220PSefety profile of subcutaneous trastuzumab in patients with HER2-positive early breast cancer: The French HERMIONE non-interventional prospective study. (23rd October 2018) - Jacquin, J-P P; Uwer, L; Savignoni, A; Ferrero, J-M; Lortholary, A; Solub, D; Attar-Rabia, H; Deblay, S; Pibre, S; Belkacemi, Y